Treatment for Pulmonary Arterial Hypertension Cleared PDF Print E-mail
Thursday, 17 September 2009 14:50
taken from http://www.flickr.com/photos/dhedwards/383835919/Renal & Urology News has recently reported in its September Issue that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to increase walk distance in patients with New York Heart Association Class III symptoms associated with WHO Group I PAH, which includes multiple etiologies such as idiopathic and familial PAH as well as PAH associated with Scleroderma and congenital heart disease.

In the TRIUMPH-1 randomized, double-blind, 12-week, placebo-controlled clinical trial, patients taking treprostinil in four daily inhalation sessions achieved a 20-meter improvement in six-minute walk distance compared with placebo recipients. The safety and effectiveness in patients with underlying lung disease has not been established. The most common side effects seen with treprostinil were cough, headache, nausea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, and diarrhea.
 
More articles :

» Beware of Skin Signs of Illness and Disease

While moisturizers and make-up, facial peels and Botox can make our skin look beautiful and young, sometimes the external skin discolorations, blemishes, blotches or other unsightly marks we seek to remove are actually signs of an underlying...

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» A System Out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

T. W. van Hal, L. van Bon, and T. R. D. J. RadstakeReceived 20 May 2011; Revised 18 August 2011; Accepted 7 September 2011Systemic sclerosis (SSc) is typified by vascular alterations and immunological disturbances and fibrosis of the skin and...

» Top 10 Scleroderma Stories For 2012

For the hundreds of thousands of people around the world, living with Scleroderma can be particularly challenging. As part of the Foundation's ongoing mission, we seek to source and provide useful information, tips, and articles which can help...

» Special Surgery Scientists To Share Advances in Lupus and Related Conditions

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of...

» Musculoskeletal Rehabilitation in the Person with Scleroderma

Janet L. PoolePosted: 03/12/2010; Curr Opin Rheumatol. 2010;22(2):205 © 2010 Lippincott Williams & WilkinsAbstractPurpose of Review: The purpose of this review is to examine current evidence for the efficacy of rehabilitation techniques for...